Phase 2b Trial of a Na(V)1.8 Inhibitor for Acute Pain
N Engl J Med. 2026 Jul 30;395(5):454-464. doi: 10.1056/NEJMoa2602910.ABSTRACTBACKGROUND: Nav1.8, a voltage-gated sodium channel expressed in the peripheral nervous system, has a critical role in pain signaling. Previous trials of NaV1.8 inhibitors have shown effectiveness in reducing postoperative pain.METHODS: We conducted a phase 2b, double-blind, randomized, placebo-controlled trial to evaluate
August 6, 2026